{
    "info": {
        "nct_id": "NCT06333951",
        "official_title": "A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)",
        "inclusion_criteria": "Inclusion Criteria\n\nSubprotocol A, B, and C\n\n* Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years).\n* Tumor tissue (formalin-fixed, paraffin-embedded sample) or an archival block must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before AMG 193 dosing.\n* Homozygous MTAP-deletion\n* Able to swallow and retain PO administered study treatment.\n* Disease measurable as defined by RECIST v1.1.\n\nSubprotocol A - Histologically or cytologically confirmed diagnosis of NSCLC.\n\nArm A (AMG 193 + carboplatin + paclitaxel + pembrolizumab):\n\n- Predominantly squamous histology.\n\nArm B (AMG 193 + carboplatin + pemetrexed + pembrolizumab):\n\n- Predominantly non-squamous histology.\n\nArm C (AMG 193 + pembrolizumab):\n\n- PD-L1 positive.\n\nSubprotocol B - Histologically confirmed NSCLC with homozygous MTAP-deletion and KRAS p.G12C mutation.\n\nSubprotocol C\n\n* Histologically or cytologically confirmed diagnosis of NSCLC with brain metastases.\n* Brain lesion meeting RANO-BM criteria for measurable disease.\n\nExclusion Criteria\n\nSubprotocol A, B, and C\n\n* Cardiovascular and pulmonary exclusion criteria as defined in the protocol.\n* Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis).\n* History of solid organ transplant.\n* Major surgery within 28 days of first dose of AMG 193.\n* Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor.\n* Radiation therapy within 28 days of first dose.\n\nSubprotocol A\n\n- Autoimmune disease or immunodeficiency disease as defined in the protocol'\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiation therapy within 28 days of first dose.",
            "criterions": [
                {
                    "exact_snippets": "Radiation therapy within 28 days of first dose.",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to first dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Arm B (AMG 193 + carboplatin + pemetrexed + pembrolizumab):",
            "criterions": [
                {
                    "exact_snippets": "AMG 193",
                    "criterion": "AMG 193 administration",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carboplatin",
                    "criterion": "carboplatin administration",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pemetrexed",
                    "criterion": "pemetrexed administration",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pembrolizumab",
                    "criterion": "pembrolizumab administration",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to swallow and retain PO administered study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Able to swallow and retain PO administered study treatment",
                    "criterion": "ability to swallow and retain orally administered study treatment",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Predominantly non-squamous histology.",
            "criterions": [
                {
                    "exact_snippets": "Predominantly non-squamous histology",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "predominant type",
                            "expected_value": "non-squamous"
                        }
                    ]
                }
            ]
        },
        {
            "line": "- PD-L1 positive.",
            "criterions": [
                {
                    "exact_snippets": "PD-L1 positive",
                    "criterion": "PD-L1 expression",
                    "requirements": [
                        {
                            "requirement_type": "expression status",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 100 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 100 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Arm C (AMG 193 + pembrolizumab):",
            "criterions": [
                {
                    "exact_snippets": "AMG 193 + pembrolizumab",
                    "criterion": "treatment assignment",
                    "requirements": [
                        {
                            "requirement_type": "assigned treatment",
                            "expected_value": [
                                "AMG 193",
                                "pembrolizumab"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Autoimmune disease or immunodeficiency disease as defined in the protocol'",
            "criterions": [
                {
                    "exact_snippets": "Autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "immunodeficiency disease",
                    "criterion": "immunodeficiency disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Arm A (AMG 193 + carboplatin + paclitaxel + pembrolizumab):",
            "criterions": [
                {
                    "exact_snippets": "AMG 193",
                    "criterion": "AMG 193 administration",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carboplatin",
                    "criterion": "carboplatin administration",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "paclitaxel",
                    "criterion": "paclitaxel administration",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pembrolizumab",
                    "criterion": "pembrolizumab administration",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 28 days of first dose of AMG 193.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 28 days of first dose of AMG 193.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Subprotocol A",
            "criterions": [
                {
                    "exact_snippets": "Subprotocol A",
                    "criterion": "subprotocol assignment",
                    "requirements": [
                        {
                            "requirement_type": "assignment",
                            "expected_value": "A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with a MAT2A inhibitor",
                    "criterion": "prior treatment with MAT2A inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... PRMT5 inhibitor",
                    "criterion": "prior treatment with PRMT5 inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Predominantly squamous histology.",
            "criterions": [
                {
                    "exact_snippets": "Predominantly squamous histology",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "predominant cell type",
                            "expected_value": "squamous"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years).",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years)",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Subprotocol C",
            "criterions": [
                {
                    "exact_snippets": "Subprotocol C",
                    "criterion": "subprotocol assignment",
                    "requirements": [
                        {
                            "requirement_type": "assignment",
                            "expected_value": "C"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of solid organ transplant.",
            "criterions": [
                {
                    "exact_snippets": "History of solid organ transplant",
                    "criterion": "solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed diagnosis of NSCLC with brain metastases.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed diagnosis of NSCLC",
                    "criterion": "NSCLC diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "NSCLC with brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Brain lesion meeting RANO-BM criteria for measurable disease.",
            "criterions": [
                {
                    "exact_snippets": "Brain lesion meeting RANO-BM criteria for measurable disease.",
                    "criterion": "brain lesion",
                    "requirements": [
                        {
                            "requirement_type": "measurability (RANO-BM criteria)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Homozygous MTAP-deletion",
            "criterions": [
                {
                    "exact_snippets": "Homozygous MTAP-deletion",
                    "criterion": "MTAP gene deletion",
                    "requirements": [
                        {
                            "requirement_type": "zygosity",
                            "expected_value": "homozygous"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cardiovascular and pulmonary exclusion criteria as defined in the protocol.",
            "criterions": [
                {
                    "exact_snippets": "Cardiovascular ... exclusion criteria as defined in the protocol",
                    "criterion": "cardiovascular exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "meets protocol-defined exclusion criteria",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary exclusion criteria as defined in the protocol",
                    "criterion": "pulmonary exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "meets protocol-defined exclusion criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumor tissue (formalin-fixed, paraffin-embedded sample) or an archival block must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before AMG 193 dosing.",
            "criterions": [
                {
                    "exact_snippets": "Tumor tissue (formalin-fixed, paraffin-embedded sample) or an archival block must be available.",
                    "criterion": "tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "formalin-fixed, paraffin-embedded sample",
                                "archival block"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before AMG 193 dosing.",
                    "criterion": "tumor biopsy before AMG 193 dosing",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Subprotocol A - Histologically or cytologically confirmed diagnosis of NSCLC.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed diagnosis of NSCLC",
                    "criterion": "NSCLC diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease measurable as defined by RECIST v1.1.",
            "criterions": [
                {
                    "exact_snippets": "Disease measurable as defined by RECIST v1.1.",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "as defined by RECIST v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Subprotocol B - Histologically confirmed NSCLC with homozygous MTAP-deletion and KRAS p.G12C mutation.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed NSCLC",
                    "criterion": "non-small cell lung cancer (NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "homozygous MTAP-deletion",
                    "criterion": "MTAP gene status",
                    "requirements": [
                        {
                            "requirement_type": "deletion status",
                            "expected_value": "homozygous deletion"
                        }
                    ]
                },
                {
                    "exact_snippets": "KRAS p.G12C mutation",
                    "criterion": "KRAS gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation",
                            "expected_value": "p.G12C"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis).",
            "criterions": [
                {
                    "exact_snippets": "Gastrointestinal tract disease causing the inability to take PO medication",
                    "criterion": "gastrointestinal tract disease",
                    "requirements": [
                        {
                            "requirement_type": "effect",
                            "expected_value": "causing inability to take PO medication"
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requirement for IV alimentation",
                    "criterion": "requirement for IV alimentation",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "gastric/jejunal tube feeds",
                    "criterion": "gastric/jejunal tube feeds",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis)",
                    "criterion": "uncontrolled inflammatory gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Subprotocol A, B, and C",
            "criterions": [
                {
                    "exact_snippets": "Subprotocol A",
                    "criterion": "subprotocol enrollment",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": "A"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subprotocol B",
                    "criterion": "subprotocol enrollment",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": "B"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subprotocol C",
                    "criterion": "subprotocol enrollment",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": "C"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Subprotocol A, B, and C",
            "criterions": [
                {
                    "exact_snippets": "Subprotocol A",
                    "criterion": "subprotocol enrollment",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": "A"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subprotocol B",
                    "criterion": "subprotocol enrollment",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": "B"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subprotocol C",
                    "criterion": "subprotocol enrollment",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": "C"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Exclusion Criteria",
            "criterions": []
        },
        {
            "line": "Inclusion Criteria",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}